Sunshine Biopharma annual debt-to-assets ratio
2018
2019
2020
2021
2022
2023
2024
2025
Sunshine Biopharma Debt-to-Assets Ratio Growth & History (SBFM)
Sunshine Biopharma's debt-to-assets ratio was 0.03 for fiscal 2025.
View full Sunshine Biopharma company overviewSunshine Biopharma annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.03 | −0.00 | −13.34% |
| 2024 | 2024-12-31 | 0.03 | 0.01 | +29.59% |
| 2023 | 2023-12-31 | 0.02 | −0.00 | −8.09% |
| 2022 | 2022-12-31 | 0.03 | 0.03 | — |
| 2021 | 2021-12-31 | 0.00 | −0.91 | — |
| 2020 | 2020-12-31 | 0.91 | 0.91 | — |
| 2019 | 2019-12-31 | 0.00 | 0.00 | — |
| 2018 | 2018-12-31 | 0.00 | — | — |
Sunshine Biopharma quarterly debt-to-assets ratio
Q4.18
Q1.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q2.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.02 | −0.01 | −30.60% |
| Q1 2026 | 2026-03-31 | 0.03 | −0.01 | −16.86% |
| Q4 2025 | 2025-12-31 | 0.03 | −0.00 | −13.34% |
| Q3 2025 | 2025-09-30 | 0.03 | 0.01 | +46.60% |
| Q2 2025 | 2025-06-30 | 0.03 | 0.01 | +47.50% |
| Q1 2025 | 2025-03-31 | 0.03 | 0.01 | +67.08% |
| Q4 2024 | 2024-12-31 | 0.03 | 0.01 | +29.59% |
| Q3 2024 | 2024-09-30 | 0.02 | −0.01 | −23.98% |
| Q2 2024 | 2024-06-30 | 0.02 | −0.01 | −22.14% |
| Q1 2024 | 2024-03-31 | 0.02 | −0.01 | −29.45% |
| Q4 2023 | 2023-12-31 | 0.02 | −0.00 | −8.09% |
| Q3 2023 | 2023-09-30 | 0.02 | 0.02 | — |
| Q2 2023 | 2023-06-30 | 0.03 | 0.03 | — |
| Q1 2023 | 2023-03-31 | 0.03 | 0.03 | — |
| Q4 2022 | 2022-12-31 | 0.03 | 0.03 | — |
| Q3 2022 | 2022-09-30 | 0.00 | — | — |
| Q2 2022 | 2022-06-30 | 0.00 | −1.13 | — |
| Q1 2022 | 2022-03-31 | 0.00 | — | — |
| Q4 2021 | 2021-12-31 | 0.00 | −0.91 | — |
| Q2 2021 | 2021-06-30 | 1.13 | 1.13 | — |
| Q4 2020 | 2020-12-31 | 0.91 | 0.91 | — |
| Q3 2020 | 2020-09-30 | 0.00 | — | — |
| Q2 2020 | 2020-06-30 | 0.00 | — | — |
| Q1 2020 | 2020-03-31 | 0.00 | −0.08 | — |
| Q4 2019 | 2019-12-31 | 0.00 | 0.00 | — |
| Q1 2019 | 2019-03-31 | 0.08 | — | — |
| Q4 2018 | 2018-12-31 | 0.00 | — | — |
Sunshine Biopharma debt-to-assets ratio trends
Over the last five fiscal years, Sunshine Biopharma's debt-to-assets ratio decreased from 0.91 to 0.03, a change of −0.88. The latest reported quarter, Q2 2026, shows 0.02.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sunshine Biopharma source filings ↗